User:Mr. Ibrahem/Netarsudil

Mr. Ibrahem/Netarsudil
Clinical data
Pronunciation	ne TAR soo dil
Trade names	Rhopressa, Rhokiinsa
Other names	AR-11324
AHFS/Drugs.com	Monograph
MedlinePlus	a618014
License data	EU EMA: by INN; US DailyMed: Netarsudil;
Routes of; administration	Eye drops, topical
Drug class	Rho kinase inhibitor
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Metabolism	Esterases in the cornea
Metabolites	AR-13503 (active metabolite)
Elimination half-life	16–17 hrs
Duration of action	≥ 24 hrs
Identifiers
	IUPAC name [4-[(2S)-3-Amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate;
Chemical and physical data
Formula	C28H27N3O3
Molar mass	453.542 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1ccc(c(c1)C)C(=O)OCc2ccc(cc2)[C@@H](CN)C(=O)Nc3ccc4cnccc4c3;
	InChI InChI=1S/C28H27N3O3/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32)/t26-/m1/s1; Key:OURRXQUGYQRVML-AREMUKBSSA-N;

Netarsudil, sold under the brand name Rhopressa and Rhokiinsa, is a medication used to treat increased intraocular pressure including open-angle glaucoma.^[3]^[1] It is used as an eye drop.^[3]

Common side effects include red eyes, conjunctival bleeding, blurry vision, and tearing.^[1] Other side effects may include bacterial keratitis.^[1] It is a rho kinase inhibitor.^[1]

Netarsudil was approved for medical use in the United States in 2017 and Europe in 2019.^[1]^[3] In the United States a 2.5 ml bottle costs about 305 USD as of 2021.^[4] It is also available as the combination netarsudil/latanoprost.^[1] It is not commercially available in Europe and the United Kingdom as of 2021.^[5]

References

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "Netarsudil Mesylate Monograph for Professionals". Drugs.com. Archived from the original on 3 June 2020. Retrieved 12 November 2021.
^ "Rhopressa- netarsudil solution/ drops". DailyMed. Archived from the original on 25 March 2021. Retrieved 2 May 2021.
^ ^a ^b ^c ^d ^e "Rhokiinsa EPAR". European Medicines Agency (EMA). 16 September 2019. Archived from the original on 29 December 2019. Retrieved 27 September 2020.
^ "Rhopressa Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 12 November 2021.
^ "Netarsudil". SPS - Specialist Pharmacy Service. 25 January 2016. Archived from the original on 13 November 2021. Retrieved 12 November 2021.

[AHFS2021-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "Netarsudil Mesylate Monograph for Professionals". Drugs.com. Archived from the original on 3 June 2020. Retrieved 12 November 2021.

[Rhopressa_FDA_label-2] "Rhopressa- netarsudil solution/ drops". DailyMed. Archived from the original on 25 March 2021. Retrieved 2 May 2021.

[EPAR2021-3] "Rhokiinsa EPAR". European Medicines Agency (EMA). 16 September 2019. Archived from the original on 29 December 2019. Retrieved 27 September 2020.

[4] "Rhopressa Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 12 November 2021.

[5] "Netarsudil". SPS - Specialist Pharmacy Service. 25 January 2016. Archived from the original on 13 November 2021. Retrieved 12 November 2021.

[1]

[2]

[3]

[4]

[5]